Clincally demonstrated, patented technology that solves problems undermining topical ophthalmic drug delivery, a $5+ billion market
Amorphex has developed a soft non-invasive device, TODDD™ to provide sustained drug delivery to the ocular surface. Comfortably concealed under the eyelid, one TODDD can deliver therapeutic levels of drug 24/7 over many months. Its polymer chemistry can incorporate a wide range of drugs. TODDD provides inherent compliance while avoiding the significant difficulties and side effects associated with eye drop delivery.